Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
25 07 2023
25 07 2023
Historique:
received:
21
08
2022
accepted:
07
04
2023
pmc-release:
25
07
2024
medline:
26
7
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Exit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk. We describe a case series of real-world de-escalations from the French NMOSD registry (NOMADMUS). All patients met the 2015 International Panel for NMO Diagnosis (IPND) diagnostic criteria for NMOSD. A computerized screening of the registry extracted patients with rituximab de-escalations and at least 12 months of subsequent follow-up. We searched for 7 de-escalation regimens: scheduled discontinuations or switches to an oral treatment after single infusion cycles, scheduled discontinuations or switches to an oral treatment after periodic infusions, de-escalations before pregnancies, de-escalations after tolerance issues, and increased infusion intervals. Rituximab discontinuations motivated by inefficacy or for unknown purposes were excluded. The primary outcome was the absolute risk of NMOSD reactivation (one or more relapses) at 12 months. AQP4+ and AQP4- serotypes were analyzed separately. We identified 137 rituximab de-escalations between 2006 and 2019 that corresponded to a predefined group: 13 discontinuations after a single infusion cycle, 6 switches to an oral treatment after a single infusion cycle, 9 discontinuations after periodic infusions, 5 switches to an oral treatment after periodic infusions, 4 de-escalations before pregnancies, 9 de-escalations after tolerance issues, and 91 increased infusion intervals. No group remained relapse-free over the whole de-escalation follow-up (mean: 3.2 years; range: 0.79-9.5), except pregnancies in AQP+ patients. In all groups combined and within 12 months, reactivations occurred after 11/119 de-escalations in patients with AQP4+ NMOSD (9.2%, 95% CI [4.7-15.9]), from 0.69 to 10.0 months, and in 5/18 de-escalations in patients with AQP4- NMOSD (27.8%, 95% CI [9.7-53.5]), from 1.1 to 9.9 months. There is a risk of NMOSD reactivation whatever the rituximab de-escalation regimen. Registered on ClinicalTrials.gov: NCT02850705. This study provides Class IV evidence that de-escalation of rituximab increases the probability of disease reactivation.
Sections du résumé
BACKGROUND AND OBJECTIVES
Exit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk.
METHODS
We describe a case series of real-world de-escalations from the French NMOSD registry (NOMADMUS). All patients met the 2015 International Panel for NMO Diagnosis (IPND) diagnostic criteria for NMOSD. A computerized screening of the registry extracted patients with rituximab de-escalations and at least 12 months of subsequent follow-up. We searched for 7 de-escalation regimens: scheduled discontinuations or switches to an oral treatment after single infusion cycles, scheduled discontinuations or switches to an oral treatment after periodic infusions, de-escalations before pregnancies, de-escalations after tolerance issues, and increased infusion intervals. Rituximab discontinuations motivated by inefficacy or for unknown purposes were excluded. The primary outcome was the absolute risk of NMOSD reactivation (one or more relapses) at 12 months. AQP4+ and AQP4- serotypes were analyzed separately.
RESULTS
We identified 137 rituximab de-escalations between 2006 and 2019 that corresponded to a predefined group: 13 discontinuations after a single infusion cycle, 6 switches to an oral treatment after a single infusion cycle, 9 discontinuations after periodic infusions, 5 switches to an oral treatment after periodic infusions, 4 de-escalations before pregnancies, 9 de-escalations after tolerance issues, and 91 increased infusion intervals. No group remained relapse-free over the whole de-escalation follow-up (mean: 3.2 years; range: 0.79-9.5), except pregnancies in AQP+ patients. In all groups combined and within 12 months, reactivations occurred after 11/119 de-escalations in patients with AQP4+ NMOSD (9.2%, 95% CI [4.7-15.9]), from 0.69 to 10.0 months, and in 5/18 de-escalations in patients with AQP4- NMOSD (27.8%, 95% CI [9.7-53.5]), from 1.1 to 9.9 months.
DISCUSSION
There is a risk of NMOSD reactivation whatever the rituximab de-escalation regimen.
TRIAL REGISTRATION INFORMATION
Registered on ClinicalTrials.gov: NCT02850705.
CLASSIFICATION OF EVIDENCE
This study provides Class IV evidence that de-escalation of rituximab increases the probability of disease reactivation.
Identifiants
pubmed: 37290967
pii: WNL.0000000000207443
doi: 10.1212/WNL.0000000000207443
pmc: PMC10435052
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
anti-aquaporin 4 autoantibody
0
Autoantibodies
0
Banques de données
ClinicalTrials.gov
['NCT02850705']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e438-e450Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 American Academy of Neurology.
Références
Arch Neurol. 2008 Nov;65(11):1443-8
pubmed: 18779415
Clin Drug Investig. 2019 Sep;39(9):909-913
pubmed: 31152369
J Neurol. 2021 Jun;268(6):2161-2168
pubmed: 33475825
Ann Neurol. 2020 Feb;87(2):256-266
pubmed: 31725931
Mult Scler Relat Disord. 2021 Jun;51:102913
pubmed: 33839482
Mult Scler. 2016 Apr;22(4):511-9
pubmed: 26199350
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
J Neurol Neurosurg Psychiatry. 2013 May;84(5):511-6
pubmed: 23138769
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
Brain Behav. 2017 Mar 14;7(4):e00671
pubmed: 28413713
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Ann Clin Transl Neurol. 2020 Sep;7(9):1477-1487
pubmed: 32767531
J Neuroinflammation. 2022 Mar 2;19(1):62
pubmed: 35236386
Rev Neurol (Paris). 2018 Apr;174(4):255-264
pubmed: 29606320
Eur J Neurol. 2021 Aug;28(8):2574-2581
pubmed: 33960076
JAMA Neurol. 2015 Sep;72(9):989-95
pubmed: 26167726
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 23;9(1):
pubmed: 34815322
J Clin Apher. 2014 Jun;29(3):171-7
pubmed: 24136389
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):486-487
pubmed: 29929977
Mult Scler Relat Disord. 2020 May;40:101927
pubmed: 31931457
Stat Med. 1998 Apr 30;17(8):857-72
pubmed: 9595616
Mult Scler Relat Disord. 2020 Jun;41:102005
pubmed: 32114369
J Neuroimmunol. 2022 Mar 15;364:577812
pubmed: 35063726
Autoimmun Rev. 2014 Oct;13(10):1055-63
pubmed: 25183241
JAMA Neurol. 2013 Sep 1;70(9):1110-7
pubmed: 23897062
Rev Neurol (Paris). 2022 Mar;178(3):249-252
pubmed: 34776261
Brain. 2012 Jun;135(Pt 6):1834-49
pubmed: 22577216
Lancet. 2019 Oct 12;394(10206):1352-1363
pubmed: 31495497
Neurology. 2021 Apr 13;96(15):e2006-e2015
pubmed: 33627499
N Engl J Med. 2019 Nov 28;381(22):2114-2124
pubmed: 31774956
Neurology. 2017 Nov 28;89(22):2238-2244
pubmed: 29093070
J Neurol. 2017 Sep;264(9):2003-2009
pubmed: 28831548
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5):
pubmed: 32587103
Mult Scler Relat Disord. 2020 Jan;37:101468
pubmed: 31683231
Front Neurol. 2022 Jan 25;12:799138
pubmed: 35145470
J Neuroimmunol. 2020 Jun 15;343:577236
pubmed: 32279020
J Clin Neurosci. 2011 Jan;18(1):43-6
pubmed: 20888238
J Neurol Sci. 2017 Feb 15;373:335-338
pubmed: 28131216
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2):
pubmed: 33622675
J Neurol Sci. 2018 Aug 15;391:72-76
pubmed: 30103975
Neurology. 2021 Nov 9;97(19):e1870-e1885
pubmed: 34610987
Mult Scler. 2016 Jun;22(7):955-9
pubmed: 26362900
Neurol Neuroimmunol Neuroinflamm. 2022 Jul 19;9(5):
pubmed: 35853752
Lancet Neurol. 2021 Sep;20(9):762-772
pubmed: 34418402
Neurol Neurochir Pol. 2017 Mar - Apr;51(2):156-162
pubmed: 28209440
J Neurol. 2015 Oct;262(10):2329-35
pubmed: 26194198
Mult Scler. 2016 Mar;22(3):329-39
pubmed: 26041804
Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809
pubmed: 30956686
Lancet Neurol. 2020 Apr;19(4):298-306
pubmed: 32199095